You just read:

Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes

News provided by

Lexicon Pharmaceuticals, Inc.

09 Jan, 2017, 08:00 ET